Breaking Finance News

JP Morgan Cazenove announced AstraZeneca PLC (LON:AZN), upholding its stock price target at 4,500.00GBX today

In a report released on 09/14/2017 JP Morgan Cazenove hold steady the stock price target of AstraZeneca PLC (LON:AZN) from 4,500.00GBX to 4,500.00GBX reporting a possible downside of -0.08%.

Previously on Wednesday September 13, 2017, Societe Generale released a statement about AstraZeneca PLC (LON:AZN) held steady the target price at 7,600.00GBX. At the time, this indicated a possible upside of 0.58%.

Just yesterday AstraZeneca PLC (LON:AZN) traded -1.61% lower at 4,887.50GBX. AstraZeneca PLC’s 50-day moving average is 4,574.38GBX and its 200-day moving average is 4,882.27GBX. The last stock price is up -0.75% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.04% over the same time period. 2,352,977 shares of AZN traded hands, up from an average trading volume of 2,257,290

Recent Performance Chart

AstraZeneca PLC (LON:AZN)

AstraZeneca PLC has 52 week low of 3,996.00GBX and a 52 week high of 5,520.00GBX with a PE ratio of 15.89 and has a market capitalization of 0 GBX.

In addition to JP Morgan Cazenove reporting its stock price target, a total of 29 brokerages have issued a ratings update on the company. The average stock price target is 61.96GBX with 4 brokerages rating the stock a strong buy, 14 brokerages rating the stock a buy, 13 brokerages rating the stock a hold, 2 brokerages rating the stock a underperform, and finally 1 brokerage rating the stock a sell.

Brief Synopsis On AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.